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ARTICLE OPEN
Medial septum activation produces opposite effects on
dopamine neuron activity in the ventral tegmental area and
substantia nigra in MAM vs. normal rats
David M. Bortz1,2,3 and Anthony A. Grace 1,2,3
The medial septum (MS) differentially impacts midbrain dopamine (DA) neuron activity via the ventral hippocampus, a region
implicated in DA-related disorders. However, whether MS regulation of ventral tegmental area (VTA) and substantia nigra pars
compacta (SNc) is disrupted in a developmental disruption model of schizophrenia is unknown. Male Sprague-Dawley rats were
exposed at gestational day 17 to methylazoxymethanol (MAM) or saline. As adults, NMDA (0.75 µg/0.2 µL) was infused into the MS,
and either DA neuron activity in the VTA and SNc (7–9 anesthetized rats per group) or amphetamine-induced hyperlocomotion
(AIH, 11-13 rats per group) was measured. MS activation produced a 58% increase in the number of spontaneously active DA
neurons in VTA and a 37% decrease in SNc in saline rats. However, MS activation produced opposite effects on DA population
activity in MAM rats, decreasing VTA DA activity by 51% and increasing SNc DA activity by 47%. MS activation also increased AIH by
113% in MAM rats, opposite of what is seen in intact rats. The effect in behavioral output may be due to disrupted GABAergic
regulation of SNc as bicuculline infusion into vSub, which selectively prevented the MS activation-induced decrease in SNc DA
activity in intact rats, prevented the increase in AIH and SNc DA activity in MAM rats. These findings demonstrate that the
regulation of midbrain DA neurons by the MS is disrupted in this well-validated animal model, suggesting that it could be a
potential locus for pharmacological intervention in disorders such as schizophrenia.
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INTRODUCTION
Schizophrenia is a devastating disorder characterized by dopamine
(DA) dysregulation in human patients1,2 and rodent models.3–5 This
dysregulation is thought to be caused by pathology within the
upstream circuits that control DA activity, such as the hippocam-
pus6–9, rather than in the DA system itself.5,10–12 As such,
characterizing the circuits that regulate DA transmission in intact
animals and animal models remains a high priority.
One brain region that is a potent regulator of DA neuron activity
in both the ventral tegmental area (VTA) and substantia nigra pars
compacta (SNc) is the medial septum (MS).13 The MS is a sub-
region of the basal forebrain that regulates DA transmission via
GABAergic and cholinergic projections to the hippocampus;13–15
two projections that are critical for hippocampal theta activity16,17
and spatial learning and memory tasks.18–20 We showed
previously that MS activation increased the number of sponta-
neously active DA neurons in the VTA via cholinergic inputs to the
ventral subiculum of the hippocampus (vSub), decreased the
number of active DA neurons in the SNc via GABAergic inputs to
vSub, and inhibited amphetamine-induced hyperlocomotion
(AIH).13 The behaviorally relevant output of the DA system is
proposed to be phasic burst-firing, driven by NMDA stimulation of
midbrain DA neurons from the pedunculopontine tegmentum.21
However, for a DA neuron to burst fire, the neuron must be
depolarized and spontaneously active; if it is hyperpolarized the
magnesium block of the NMDA channel prevents NMDA-driven
burst firing.21–23 Therefore, by regulating the number of neurons
that are spontaneously active, the MS to midbrain pathway
controls the “gain” of the burst firing “signal”, effectively setting a
“context” for behaviorally relevant DA transmission from both the
VTA and SNc.13,24
The pathway by which the MS regulates DA activity in both the
VTA and SNc requires the vSub, a region that has been heavily
implicated in schizophrenia.3,5–7 Furthermore, the GABAergic
projections from MS are known to contact parvalbumin-positive
interneurons in the hippocampus,14,25 which is the interneuron
class that has been specifically implicated in the hyperactive
hippocampal activity and downstream-elevated DA release seen
in patients26,27 and animal models.28 Therefore, it is important to
further examine the regulation of DA transmission by the MS in an
animal model that recapitulates the constructs of decreased
parvalbumin interneurons and hippocampal hyperactivity in order
to determine if the MS could be a potential locus for disruption in
schizophrenia.
Thus, we examined the MS to midbrain pathway in a well-
validated animal model of hippocampal-dependent DA disruption
—by prenatal (GD17) administration of methylazoxymethanol
acetate (MAM).5,29 We performed electrophysiological recordings
of VTA and SNc spontaneous DA activity in MAM and saline-
treated (Sal) rats after NMDA or vehicle infusion into the MS, and
examined the behavioral consequence of MS activation using the
AIH paradigm.
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RESULTS
MAM treatment causes MS activation to produce opposite effects
on VTA and SNc DA neuron activity compared to Sal rats
To determine if the MS regulation of VTA and SNc DA neuron
activity is disrupted in the MAM model, adult male anesthetized
MAM and Sal rats (N= 8–9 rats per group) were infused with
NMDA (0.75 µg in 0.2 µL) or dPBS into the MS (Fig. 1d) and DA
neurons were recorded in the VTA or SNc in nine sequential tracks
(Fig. 1a,b). MS activation produced significantly different effects on
DA neuron activity in MAM vs. Sal rats in the VTA (overall ANOVA:
F3, 29= 16.12, P < 0.0001, see Fig. 2a). In Sal rats, MS activation
produced a 58% increase in the number of active DA neurons per
recording track in the VTA (mean ± SEM; Sal/dPBS: 1.2 ± 0.2, Sal/
NMDA: 1.9 ± 0.1 neurons/track, Tukey’s: P= 0.0037), similar to
what has been shown previously in intact animals.13 In contrast,
MAM rats, whose elevated basal level of DA neuron activity (MAM/
dPBS: 1.9 ± 0.1 neurons/track) has been shown in previous
studies,3 displayed an opposite 47% reduction in the number of
active DA neurons recorded in the VTA after MS activation (MAM/
NMDA: 1.0 ± 0.1 neurons/track, Tukey’s: P < 0.0001; Tukey’s Sal/
NMDA vs. MAM/NMDA: P < 0.0001; Table 1). Spike frequency and
the percentage of spikes in bursts in the VTA were not affected by
MAM treatment or MS activation (P > 0.1, Fig. 2A).
MS activation also produced significantly different effects on DA
neuron activity in MAM vs. Sal rats in the SNc (overall ANOVA: F3,
29= 14.82, P < 0.0001, Fig. 2B). MS activation produced a 37%
decrease in the number of active DA neurons per recording track
in Sal rats (Sal/dPBS: 1.9 ± 0.1, Sal/NMDA: 1.2 ± 0.1 neurons/track,
Tukey’s: P= 0.0136), similar to what has been shown previously in
intact animals.13 Different from what has been reported in the
VTA, MAM rats showed no effect of MAM treatment on basal
spontaneous DA neuron activity in the SNc (MAM/dPBS: 1.7 ± 0.2
neurons/track). However, as with the VTA, MS activation produced
an opposite response in the SNc of MAM rats (47% increase, MAM/
NMDA: 2.5 ± 0.2 neurons/track, Tukey’s: P= 0.0012) that was
significantly different from what was seen in the Sal rats (Tukey’s
Sal/NMDA vs. MAM/NMDA: P < 0.0001; Table 1). Spike frequency
and the percentage of spikes in bursts in SNc were not affected by
MAM treatment or MS activation (P > 0.1, Fig. 2B).
Fig. 1 Representative placements, DA neuron identification, and drug infusion locations. a Population activity in the VTA was measured in
nine sequential electrode tracks between AP −5.3 to 5.7 and ML 0.6–1.0. Arrows indicate three tracks across the medial–lateral span of the
VTA. b Population activity is measured similarly in the SNc, between AP −4.9 to 5.3 and ML 2.0–2.4. Following the conclusion of the 9th track
(top arrows), Chicago Sky Blue is ejected from the electrode leaving a blue dot for histological verification (bottom arrow). c Representative DA
recording from the VTA and individual spike. The time bar for representative tracing equals 1 s, demonstrating a frequency of approximately
six spikes per second. Arrows indicate three sets of spikes that are occurring in bursts. The time bar under the individual spike is 1.1 ms.
Representative histology and matching illustration for the target region of the d MS and e vSub. The line in the illustration denotes the
cannula placement and the arrow indicates the ventral termination of the cannula track
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MAM treatment causes MS activation to produce opposite effects
on AIH compared to Sal rats
To determine the impact of MS activation on locomotor behavior
in MAM vs. Sal rats, the rats were infused with NMDA (0.75 µg in
0.2 µL) or dPBS into the MS and the total distance traveled (cm) in
an open field arena was measured before and after systemic
amphetamine injection (0.75 mg/kg, N= 11–13 rats per group).
MS activation significantly reduced locomotor behavior before
amphetamine injection (at 5 min) compared to Sal/dPBS and
MAM/dPBS groups (Tukey’s: P < 0.05, see Fig. 3). Following
amphetamine injection, MS activation produced opposite effects
on locomotor behavior in MAM vs. Sal rats (overall two-way
ANOVA (time point × intracranial drug condition): F51, 731= 2.429,
P < 0.0001, Tukey’s Sal/NMDA vs. MAM/NMDA: 35min: P < 0.0001,
40min: P= 0.0435). This effect was primarily caused by a sharp
spike in locomotion in the MAM/NMDA rats in the first epoch
following amphetamine injection, which was different from all
other groups (Tukey’s: P’s < 0.05, see Fig. 3) and opposite of the
reduction seen following MS activation in Sal and intact rats (Table
1).13 The difference in locomotor behavior between MAM and Sal
rats following MS activation was not likely driven by changes in
stereotypy, as MS activation did induce an increase in stereotypy
(main effect of MS activation, F3, 25= 4.967, P= 0.0077), but it was
Fig. 2 MS activation produced opposite effects on DA neuron activity in saline vs. MAM rats. a NMDA activation of the MS increased DA
neuron population activity in the VTA compared to vehicle (dPBS; mean ± SEM). MAM rats displayed elevated DA activity compared to Sal
animals, but showed an opposite decrease in DA activity following MS activation (*Tukey’s P < 0.05). Spike frequency and bursting activity in
VTA were not affected by MAM treatment or MS activation. b NMDA activation of the MS decreased DA neuron population activity in the SNc
compared to vehicle (dPBS). DA population activity in the SNc of MAM rats was not different from Sal rats at baseline, but showed an opposite
increase in DA activity following MS activation (*Tukey’s P < 0.05). Spike frequency and bursting activity in SNc were not affected by MAM
treatment or MS activation. Black dots indicate data from individual rats (N= 8–9 rats per group in both VTA and SNc)
Table 1. Summary of changes in DA neuron activity and AIH in
different treatment groups
Treatment MS infusion vSub infusion VTA DA
activity
SNc DA
activity
AIH
Intact13 dPBS N/A 1.0 ± 0.1 1.7 ± 0.1 N/A
Intact13 NMDA N/A 1.8 ± 0.1;↑ 1.1±0.2;↓ ↓
Sal dPBS N/A 1.2±0.2; – 1.9 ± 0.1; – –
Sal NMDA N/A 1.9 ± 0.1;↑ 1.2±0.1↓ ↓
MAM dPBS N/A 1.9 ± 0.1;↑ 1.7 ± 0.2; – –
MAM NMDA N/A 1.0 ± 0.1; – 2.5 ± 0.2;↑ ↑
MAM NMDA Bicuculline N/A 1.4 ± 0.2; – –
MAM dPBS Bicuculline N/A 1.7 ± 0.2; – –
Numbers indicate the neurons/track mean ± SEM for that treatment group.
Symbols denote the change (increase, decrease, or no change) in the
respective category compared to the intact/dPBS group published
previously13
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not different between MAM and Sal rats (P > 0.05; see Supple-
mentary Figure 1).
Effects on AIH and SNc DA activity in MAM rats are mediated by
GABAergic inputs to vSub
Our previous studies indicated that vSub bicuculline infusions
selectively prevented the MS activation-induced decreases in SNc
DA activity and reversed the reduction in AIH in intact rats.13 This
suggested that these effects were both driven by GABAergic
inputs to vSub, likely from the MS. To determine if the disruptions
in AIH and SNc DA neuron activity were also mediated by
GABAergic inputs to vSub, MAM rats were infused with bicuculline
in the vSub (Fig. 1E; N= 11–12 rats per group, Bicuc; 12.5 ng in
0.5 µL) just prior to NMDA or dPBS activation of the MS. In
accordance with this hypothesis, bicuculline infusion in MAM rats
prior to MS activation completely prevented the increase in AIH
(Fig. 4, overall two-way ANOVA (time point × intracranial drug
condition): F51, 756= 1.629, P= 0.0044, Tukey’s MAM/NMDA vs.
MAM/NMDA/Bicuc: 35min: P < 0.0041; Table 1). Interestingly, the
reduction in locomotor behavior in the NMDA-treated rats in the
first 5-min epoch was not prevented by bicuculline (Tukey’s vs.
MAM/dPBS and MAM/dPBS/Bicuc: P’s < 0.05), suggesting this
effect is likely mediated via a different pathway.
Bicuculline infusion also prevented the MS activation-induced
increase in DA activity in the SNc of MAM rats (N= 7 rats; Fig. 5).
Bicuculline infusion reduced the number of active DA neurons in
the SNc by 44% (MAM/NMDA/Bicuc: 1.4 ± 0.2 neurons/track) to a
level comparable to the MAM/dPBS rats (1.7 ± 0.2 neurons/track)
and significantly reduced from the MAM/NMDA rats (2.5 ± 0.2
neurons/track, F2, 20= 11.8, P= 0.0004, Tukey’s: P= 0.0004; Table
1). Bicuculline infusion also significantly reduced the percentage
of spikes occurring in bursts compared to both other groups (F2,
20= 6.184, P= 0.0081), but did not affect spike frequency.
DISCUSSION
These experiments resulted in several findings. First, this study
reports that MAM treatment did not impact baseline DA activity in
the SNc, which is markedly different than the large increase in
baseline activity seen in the VTA in MAM rats. Second, the MS-
mediated regulation of VTA and SNc DA neuron activity seen in
intact13 and Sal-treated rats was disrupted by prenatal MAM
Fig. 3 MS activation produced opposite effects on AIH in saline vs. MAM rats. NMDA (0.75 µg in 0.2 µL) activation of the MS significantly
reduced basal locomotor behavior at the first time point in both MAM and Sal rats (mean ± SEM; d= Tukey’s P < 0.05). MAM rats showed
significantly elevated AIH 5min following amphetamine injection (indicated by dashed line, 0.75 mg/kg; at 35min), compared to all other
groups (a,b,c= Tukey’s P < 0.05) and compared to Sal/NMDA rats at minute 40 (a= Tukey’s P < 0.05). Inset: The total distance travelled (cm) for
each group is summed over two key intervals—minute 0 to 15 and minute 30 to 45. The dashed line indicates when the amphetamine was
infused. MAM/NMDA rats had significantly elevated locomotion in the first 15 min after amphetamine compared to Sal/NMDA rats (*P= 0.009)
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treatment. MAM-treated rats displayed a decrease in DA neuron
activity in the VTA and an increase in the SNc following MS
activation, which is opposite of the pattern seen in intact and Sal
rats. Third, MAM rats also displayed the opposite pattern of
locomotor activity following amphetamine challenge, with MS
activation increasing AIH in MAM rats instead of decreasing it as it
did in intact rats. Finally, the increase in AIH was likely driven by a
disruption in the GABAergically mediated control of the SNc as
bicuculline infusion into the vSub prior to MS activation, which
was previously shown to selectively affect SNc DA neuron activity
and not VTA DA activity in intact rats,13 reversed the increase in
both AIH and SNc DA activity in MAM rats.
Proposed circuit contributing to disruption of MS-DA regulation in
MAM rats
The MS has been shown previously to regulate AIH and DA
population activity in the VTA and SNc of intact rats via a multi-
synaptic pathway (Supplementary Figure 2) that projects through
the ventral hippocampus and ventral pallidum.13 The ability of this
pathway to regulate DA activity has also been shown by direct
modulation of the ventral hippocampus,30 nucleus
accumbens,30,31 and ventral pallidum,13,21,32 providing evidence
for the specific circuit that is likely to mediate the effects shown
here. Furthermore, the vSub of the hippocampus has been shown
to be critical for the differential regulation of the VTA and SNc by
the MS, as direct infusion of cholinergic or GABAergic antagonists
into the vSub selectively modulates MS-mediated DA activity in
the VTA or SNc, respectively.13 Importantly, the manipulations in
these papers are not pathway-specific, so other long-loop
pathways involving interconnected regions that also affect
midbrain DA activity, such as the prefrontal cortex or amyg-
dala,33–35 could play a role in the effects reported. However, the
ability to modulate DA activity at every brain region in the
pathway indicates that the pathway described is the most
parsimonious circuit explanation for MS mediation of the VTA
and SNc.
Here, we demonstrate that prenatal MAM treatment disrupts
MS mediation of both VTA and SNc and AIH. While MAM has been
shown to result in limbic and cortical thining,36 due primarily to
dendritic arbor reduction and loss of restricted classes of
interneurons,28,37 major brain distortions are not evident. Further-
more, infusion of NMDA to sites directly adjacent to the MS in
Fig. 4 Activation of AIH in MAM rats is blocked by vSub bicuculline infusions. Bicuculline (Bicuc; 12.5 ng in 0.5 µL) infusion into the vSub just
prior to MS activation prevented the increase in amphetamine-induced hyperlocomotion (amphetamine injection marked by dashed line),
restoring locomotor behavior back to MAM/ dPBS levels (mean ± SEM; a,b,c,d,e= Tukey’s test P < 0.05). Inset: The total distance travelled (cm)
for each group is summed over two key intervals—minute 0 to 15 and minute 30 to 45. The dashed line indicates when the amphetamine was
infused
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intact rats did not result in DA activity changes similar to those
seen after MS activation.13 As such, gross changes to MS
connectivity by MAM leading to activation of regions other than
the MS is not likely to be the cause of the DA and AIH
dysregulation shown here. However, a consistent finding in MAM-
treated rats is a significant loss of parvalbumin-positive inter-
neurons in the vSub.28,37 This interneuron class has been shown to
be one of the cellular targets of GABAergic projections from
MS,14,25 and the vSub is required for MS-mediated DA activity
changes in both VTA and SNc.13 Therefore, one possibility is that
the differential effect of MS activation on DA activity and AIH in
MAM vs. Sal rats is driven by a loss of GABA-GABA connectivity in
vSub. For example, when the MS is activated in Sal or intact rats,
GABA from the MS GABAergic projection to vSub15,38 activates
GABAA receptors on interneurons, which tend to be more sensitive
to GABA than primary neurons.39–41 This would inhibit vSub
interneurons, disinhibiting pyramidal cells, and combined with MS
cholinergic projections activating pyramidal cells,14,15,42 would
result in an increase in hippocampal activity. This is consistent
with our previous finding that TTX inactivation of the vSub
prevented MS-mediated changes in both VTA and SNc.13 When
the MS is activated in MAM rats, GABA release in vSub would likely
reach both interneurons and pyramidal cells because of the loss of
higher-sensitivity interneuron targets. This would lead to an
opposite decrease in pyramidal cell activity, possibly explaining
how DA activity, and subsequently AIH, could be opposite in MAM
compared to Sal animals. Furthermore, bicuculline infusion into
the vSub, which would prevent GABA inhibition of both
interneurons and pyramidal cells, brings DA activity in SNc and
AIH back to baseline levels (see Figs. 4 and 5).
Proposed mechanism for early epoch effects on AIH
NMDA activation of the MS reduced baseline open field locomotor
behavior in both Sal and MAM rats (Fig. 3, minute 5), suggesting it
was unaffected by MAM treatment. Additionally, this effect was
not blocked by bicuculline infusion into the vSub (Fig. 4)
suggesting that it is not likely regulated via the previously
described vSub to SNc pathway (Supplementary Figure 2).
Therefore, since MAM treatment is known to increase DA activity
in the VTA29,36 and vSub bicuculline infusions are known to affect
MS-driven DA activity changes in the SNc,13 it is possible that this
baseline locomotor effect is not driven by changes within the DA
system. The reduction in locomotor behavior following MS
activation is, however, in line with previous studies suggesting
that combined lesion of the septohippocampal GABAergic and
cholinergic projections results in an increase in baseline locomotor
behavior.43 One possibility is that locomotion was decreased due
to an increase in grooming behavior. This notion is supported by
the finding that MS activation resulted in a greater degree of
amphetamine-induced stereotypy that was similarly unaffected by
MAM treatment (Supplementary Figure 1).
Behavioral implications
It has been hypothesized that the primary behavioral consequence
of MS activation, which leads to an increase in VTA DA activity and
a decrease in SNc DA activity in intact animals,13 could be an
attenuation of SNc-driven impulsive responding34ef>,44,45 in favor
of VTA-driven goal directed responding.34,45 This could produce a
“stop and consider alternate possibilities” mode of responding
in situations where reward contingencies had changed. This
concept is supported by data showing that septohippocampal
lesions increase perseverative responding and proactive interfer-
ence and decrease fear extinction.19,46 The results in this paper
indicate that MAM-treated animals display the opposite pattern of
midbrain DA activity and a significant increase in AIH in response
to MS activation. This could suggest that the behavioral effect of
MS activation in MAM rats would be to act impulsively, choosing
without consideration for changing situational and environmental
contingencies. Interestingly, this behavioral disposition is a hall-
mark of MAM rats47 and schizophrenia patients48 as demonstrated
clearly in reversal learning and cognitive flexibility tasks. Therefore,
it is possible, although speculative, that disruptions in the MS’s
regulation of the DA system could play a role in the cognitive
flexibility deficits seen in schizophrenia patients.
Selective MS activation as a potential treatment strategy
An interesting finding from this paper is that MS activation
reduced VTA DA activity in MAM rats back to intact baseline levels,
~1.0 active DA neuron per recording track. This probably occurred
due to an increase in pyramidal cell inhibition (see proposed circuit
section above), thus compensating for the interneuron loss that is
a hallmark in MAM rats.28,37 This might suggest that manipulation
of the MS-vSub pathway could have the potential to reverse the
hyperactive DA state seen in MAM3,29 and schizophrenia.49–51
However, the decrease in VTA DA population activity was
coincident with a potentially pathological increase in SNc DA
activity and AIH. Such a condition has the potential to result in an
Fig. 5 The MS activation-induced increase in SNc DA neuron activity was prevented by vSub bicuculline infusion. Bicuculline (Bicuc; 12.5 ng in
0.5 µL) infusion into the vSub just prior to MS activation prevented the increase in SNc DA neuron activity, with DA activity remaining at MAM/
dPBS levels (mean ± SEM; *Tukey’s P < 0.05). Bicuculline infusions also significantly reduced the percentage of spikes occurring in bursts
compared to both other groups (*Tukey’s P < 0.05). Black dots indicate data from individual rats (N= 7–8 rats per group)
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increase in habit-related, impulsive responding that is typical of
dorsal striatal DA release (see behavioral implications above).34,44,45
Therefore, it is unlikely that general activation of the MS would be
cognitively beneficial in MAM animals or patients. Alternatively, it
was previously shown that MS-mediated VTA and SNc DA activity
could be selectively modulated via different sub-regions of the
ventral pallidum and different neurotransmitter inputs to vSub.13
Furthermore, we demonstrated that infusion of bicuculline into the
vSub, which prevented the MS-mediated increase in SNc DA
activity without affecting the VTA,13 was able to reverse the
behavioral deficit in AIH, bringing MAM/NMDA rats back to Sal/
dPBS locomotion levels. Therefore, selective manipulation of the
MS to midbrain pathway might be able to reverse the hyperactive
DA state in the VTA without increasing DA activity in the SNc,
potentially alleviating the hyperdopaminergic state seen in the
disease without inducing other non-specific effects.
Summary
This manuscript demonstrates that the MS-mediated regulation of
DA neuron activity in the VTA and SNc and AIH is disrupted in
MAM-treated rats, leading to an opposite response in both DA
activity and behavior compared to Sal and intact rats. The elevation
in SNc DA activity and AIH were both reversed by blocking
GABAergic inputs in the vSub, implicating the ventral hippocampal
GABAergic system as a primary locus for disruption in the model.
Based on the known role of the MS in cognition, these data
suggest that a disruption in the MS’s regulation of DA activity could
play a role in the expression of hallmark schizophrenia deficits,
such as increased impulsivity and decreased cognitive flexibility;
thus highlighting selective manipulation of the MS as a potential
locus for therapeutic efficacy in schizophrenia.
METHODS
Animals
Timed pregnant Sprague Dawley rats were obtained from Envigo and
treated with MAM (20mg/kg i.p.) or Sal at gestational day 17. Male MAM or
Sal pups were weaned and pair-housed with ad libitum access to food and
water in a temperature and humidity controlled room until used for
experiments at adulthood (PD60–90). Experimental procedures were
approved by the Institutional Animal Care and Use Committee of the
University of Pittsburgh according to National Institute of Health Guide for
the Care and Use of Laboratory Animals.
Electrophysiological recordings
MAM and Sal rats were anesthetized with an initial dose of chloral hydrate
(400mg/kg i.p.), secured to a stereotaxic frame (Kopf), and implanted with
a guide cannula in the (MS; AP: +0.5, ML: 0, DV: −5.8 mm from bregma) as
previously described.13 NMDA (0.75 µg in 0.2 µL; Sigma Aldrich) mixed in
Dulbecco’s phosphate buffered saline (dPBS; Sigma Aldrich) or dPBS alone
was then infused (0.5 µL/min) just prior to electrophysiological recording of
the VTA or SNc. Chemical stimulation was used for these experiments to
produce stable, long-duration excitation, and the dose of NMDA used
corresponded with previous studies.13,21,22,30,52 For experiments involving
intrasubiculum infusions, bicuculline (12.5 ng in 0.5 µL) was infused (AP:
−6.0, ML: 4.5 in mm from bregma, DV: −8.5 in mm from skull) just prior to
NMDA activation of the MS in separate animals, using the same procedure.
Following drug infusions, glass recording electrodes were lowered into
the VTA or SNc in nine sequential vertical tracks (see Fig. 1). The number of
active DA neurons recorded within an animal was averaged across the
total number of tracks recorded (neurons/track) to yield a measure of
population activity. Coordinates were determined using an atlas.53 The
recording pattern has been previously described13,54 and uses well-
established identification criteria to identify DA neurons.55,56 Once
identified, neurons were recorded for 3 minutes and assessed for firing
rate and burst firing properties (burst= action potentials occurring with an
interspike interval of ≤80ms and terminating with an interspike interval of
>160ms).57 At the conclusion of the ninth track, electrophoretic ejection of
Chicago sky blue dye marked the recording location for histological
confirmation of electrode site.
AIH and stereotypy
MAM and Sal rats were implanted with guide cannulae into the MS or into
both the MS and vSub as previously described.13 Following a one week
recovery period, rats were infused with either NMDA or dPBS in the MS
(Fig. 3) or NMDA or dPBS in the MS and bicuculline in the vSub (Fig. 4)
10min before being placed in an open-field arena (Coulborn). Locomotor
activity was measured by beam breaks in the x–y plane and analyzed in
5min epochs. Systemic injections of D-amphetamine (0.75 mg/kg) were
given after a 30min baseline period, and the post-amphetamine session
lasted for 60min. This allowed us to determine the effect of long-duration
MS activation on both baseline locomotion and the transient hyperloco-
motion induced by amphetamine injection. Following the locomotor test,
rats were given an additional injection of amphetamine (2 mg/kg), placed
in a small metal cage, and observed to measure their stereotyped
behavior. Stereotypic behaviors; including oral stereotypy, sniffing, rearing,
vigorous grooming, and climbing, were scored three times during each 5-
min epoch on a 0–3 scale.58,59 This yielded a value between 0 and 9 for
each 5 min bin during the 45-min observation period, with 9 indicating the
highest degree of stereotyped behavior.
Histology
Following each experiment, MAM and Sal rats were sacrificed for
histological verification of cannula and electrode placement according to
a stereotaxic atlas53 as previously described.13
Statistical analysis
Detection and analysis of DA neuron activity was performed using
LabChart and NeuroExplorer, and locomotor behavior was recorded using
TruScan software. Dependent measures included DA population activity,
neuron firing rate, percentage of spikes occurring in bursts, and total
distance traveled (cm). All measures (reported as mean ± SEM), were
analyzed by ANOVA. For electrophysiology experiments a one-way ANOVA
was performed using intracranial drug condition (combination of
intracranial drug infusions, example MS NMDA or MS NMDA/vSub bicuc)
as a between-subjects variable. AIH was analyzed using a two-way ANOVA
with intracranial drug condition (combination of intracranial NMDA/dPBS
or bicuculline infusions) as a between-subjects variable and time point
(5 min epochs) as a within-subjects variable. Post-hoc analyses were
performed using the Tukey’s test. Significance is defined as P < 0.05 (IBM
SPSS Statistics 22).
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